Lazarus J H, Marchant B, Alexander W D, Clark D H
Clin Endocrinol (Oxf). 1975 Nov;4(6):609-15. doi: 10.1111/j.1365-2265.1975.tb01930.x.
35S-methimazole (MMI), 35S-carbimazole or 35S-propylthiouracil (PTU) were given orally to fifty-five patients at various times up to 12 h before surgical thyroidectomy. The amount of 35S radioactivity and labelled drug in thyroid and plasma samples was measured. Intrathyroidal inhibition or organic binding of iodine by MMI, carbimazole and PTU was measured after intravenous administration of 131I, 132I or 125I-iodide. After administration of 35S-carbimazole or 35S-MMI the thyroid to serum (T/S) ratio of 35S radioactivity was greater in thyrotoxic glands than in non-toxic adenoma tissue. 35S-MMI was found in thyroid and plasma samples after administration of 35S-carbimazole. The T/S 35S-MMI was greater than 1 in most but not all patients. 35S radioactivity was also concentrated in the thyroid after administration of 35S-PTU. In thyrotoxic glands there was an 80% inhibition of iodine organification in patients receiving MMI and 60% for those receiving PTU. It is suggested that carbimazole and MMI can be given once or twice daily in some patients but PTU would be less suitable for this dose schedule.
在甲状腺切除术前12小时内的不同时间,给55例患者口服35S-甲巯咪唑(MMI)、35S-卡比马唑或35S-丙硫氧嘧啶(PTU)。测量甲状腺和血浆样本中的35S放射性及标记药物含量。静脉注射131I、132I或125I-碘化物后,测量MMI、卡比马唑和PTU对甲状腺内碘的抑制作用或有机结合。给予35S-卡比马唑或35S-MMI后,甲状腺毒症腺体中35S放射性的甲状腺与血清(T/S)比值高于非毒性腺瘤组织。给予35S-卡比马唑后,在甲状腺和血浆样本中发现了35S-MMI。大多数但并非所有患者的T/S 35S-MMI大于1。给予35S-PTU后,35S放射性也集中在甲状腺中。在甲状腺毒症腺体中,接受MMI的患者碘有机化受到80%的抑制,接受PTU的患者受到60%的抑制。建议在某些患者中,卡比马唑和MMI可以每日给药一次或两次,但PTU不太适合这种给药方案。